Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher L Nobles

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
The Journal of Clinical Investigation|December 18, 2019
CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integrationChristopher L Nobles, Scott Sherrill-Mix, John K Everett, et al.
Blood|February 11, 2020
Clonal tracking in gene therapy patients reveals a diversity of human hematopoietic differentiation programsEmmanuelle Six, Agathe Guilloux, Adeline Denis, et al.
The Journal of Clinical Investigation|December 10, 2020
Antigen-driven clonal selection shapes the persistence of HIV-1-infected CD4+ T cells in vivoFrancesco R Simonetti, Hao Zhang, Garshasb P Soroosh, et al.
Nature Medicine|October 3, 2018
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cellMarco Ruella, Jun Xu, David M Barrett, et al.
Nature|February 3, 2022
Decade-long leukaemia remissions with persistence of CD4<sup>+</sup> CAR T cellsJ Joseph Melenhorst, Gregory M Chen, Meng Wang, et al.
Nature|June 1, 2018
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cellsJoseph A Fraietta, Christopher L Nobles, Morgan A Sammons, et al.
Science (New York, N.Y.)|February 8, 2020
CRISPR-engineered T cells in patients with refractory cancerEdward A Stadtmauer, Joseph A Fraietta, Megan M Davis, et al.
Nature Medicine|March 22, 2022
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trialVivek Narayan, Julie S Barber-Rotenberg, In-Young Jung, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The Journal of Clinical Investigation|December 18, 2019
CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integrationChristopher L Nobles, Scott Sherrill-Mix, John K Everett, et al.
Blood|February 11, 2020
Clonal tracking in gene therapy patients reveals a diversity of human hematopoietic differentiation programsEmmanuelle Six, Agathe Guilloux, Adeline Denis, et al.
The Journal of Clinical Investigation|December 10, 2020
Antigen-driven clonal selection shapes the persistence of HIV-1-infected CD4+ T cells in vivoFrancesco R Simonetti, Hao Zhang, Garshasb P Soroosh, et al.
Nature Medicine|October 3, 2018
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cellMarco Ruella, Jun Xu, David M Barrett, et al.
Nature|February 3, 2022
Decade-long leukaemia remissions with persistence of CD4<sup>+</sup> CAR T cellsJ Joseph Melenhorst, Gregory M Chen, Meng Wang, et al.
Nature|June 1, 2018
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cellsJoseph A Fraietta, Christopher L Nobles, Morgan A Sammons, et al.
Science (New York, N.Y.)|February 8, 2020
CRISPR-engineered T cells in patients with refractory cancerEdward A Stadtmauer, Joseph A Fraietta, Megan M Davis, et al.
Nature Medicine|March 22, 2022
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trialVivek Narayan, Julie S Barber-Rotenberg, In-Young Jung, et al.
Pageof 2